Eli Lilly and Company has announced that its Taltz (ixekizumab) 80mg/mL injection is now available in a new citrate-free formulation.
The latest decision comes after the US Food and Drug Administration (FDA) received approval in May this year for the new formulation, which includes the same active ingredient as the original formulation.
The monoclonal antibody taltz (ixekizumab) is designed to selectively bind to interleukin 17A (IL-17A), a natural cytokine involved in normal inflammatory and immune responses, and inhibit its interaction with the IL-17 receptor.
It has been approved for the treatment of moderate to severe plaque psoriasis in people aged six years and older who are candidates for systemic therapy or phototherapy.
The antibody has also been approved to treat adult patients with active ankylosing spondylitis (AS), active psoriatic arthritis and active non-radiographic axial spondyloarthritis (nr-axSpA) with objective inflammatory signs.
The company said the new formulation of Taltz injection significantly reduced pain at the injection site and demonstrated an 86% decrease in pain on a visual analogue scale (VAS) compared to the formulation of origin.
It also showed a safety profile consistent with the original formulation.
Lilly Immunology U.S. Vice President Ashley Diaz-Granados said, “Taltz has a long history of providing an effective treatment with a well-established safety profile that addresses the symptoms of people with plaque psoriasis, psoriatic arthritis, AS and nr-axSpA.
“We are proud of our investment in research that puts the patient experience at the centre.
“This new formulation provides an additional reason to choose Taltz, and we look forward to introducing it to patients who have not yet tried Taltz and providing a smooth transition for those who are already experiencing the drug’s benefits.”
Now, patients who are already receiving treatment with Taltz do not need a new prescription.
Currently, citrate-free Taltz is shipping across the United States and should be available in other countries by the end of the month.
In December last year, the European Medicines Agency approved the citrate-free version of the antibody.